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View Article Online1. Introduction
Superparamagnetic iron oxide NPs, with core diameters between
3 and 15 nm, are used in a rapidly expanding number of research
and practical applications in the biomedical field; the most
common include magnetic cell labeling,1,2 separation3 and
tracking,3 for therapeutic purposes in hyperthermia4,5 and drug
delivery,6 and for diagnostic purposes, e.g., as contrast agents for
magnetic resonance imaging (MRI)7–9 (Fig. 1). Super-
paramagnetic iron oxide NPs are considered to be benign to the
body7,10 mainly because iron oxide is dissolved under acidic
conditions. The resulting Fe3+ ions can be fed into the natural
iron storage which is 3–5 g iron for an adult human.11,12 Thus the
additional amount of iron released from dissolved iron oxide
NPs is negligible if iron oxide NP concentrations in the mg kg1
body weight range are injected.13 Most other magnetic materials
such as Co have a higher saturation magnetization (Ms)
compared to iron oxide14 and would therefore show a stronger
magnetic response, but are toxic, which provides iron oxide with
a decisive advantage for the majority of biomedical
applications.15
To enable that superparamagnetic iron oxide NPs can be
dispersed in aqueous media and at physiologic salt concentra-
tions, iron oxide cores are coated with polymers, so-called
dispersants. Without a polymer shell NPs will rapidly aggregate
through interactions between themselves or with biological
molecules and precipitate out of solution. Commercially avail-
able superparamagnetic iron oxide NPs intended for magnetic
labeling, cell separation purposes and as MR contrast agents are
typically coated with sugars such as dextran or synthetic poly-
mers such as silicone.16 The reversible adsorption of these
dispersants which have molecular weights (Mws)$ 10 kDa is due
to poor affinity of the repeat units towards iron oxide.17 There-
fore these dispersants often enwrap and cluster multiple iron
oxide NP cores by direct physisorption to multiple NP surfaces.
However, the control over cluster size is poor (Fig. 2a).18–21Erik Reimhult
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2820 | Nanoscale, 2011, 3, 2819–2843Alternatively, superparamagnetic iron oxide NPs can be
stabilized with low Mw < 10 kDa dispersants consisting of
a polymer spacer with a covalently bound anchor that has high
affinity for the NP surface (Fig. 2b). Dispersants self-assemble on
the NP surface in a well-defined adsorption geometry through
anchors. The resulting core–shell NPs can be divided into four
components, namely the core, anchor, spacer and optional
surface functionalities (Fig. 2b). Each of these components can
independently be adjusted through the modular build-up and
defined geometry, rendering such NPs very versatile for a multi-
tude of applications.22,23 One of the resulting advantages of this
modular and controlled build-up is that the hydrodynamic size of
these NPs can be precisely controlled in contrast to NPs with
dispersant shells consisting of physisorbed high Mw dispersants.
Furthermore, the well-defined assembly of dispersants at the NP
surface enables controlled surface presentation of functionalities.
NP size, stability, dispersant shell thickness and control over
functionalities presented at the NP surface are the factors that
critically determine NP performance in the demanding environ-
ment of a biological fluid.24,25 These parameters are largely
determined by the dispersant shell of NPs. Therefore, dispersants
are of pivotal importance for the performance and further
development of NPs.
This review is focused on different aspects of NP stability,
from its practical definition to its implementation by molecular
design of the surrounding shell and further on to its influence on
the magnetic properties of the superparamagnetic iron oxide
NPs. In order to define and investigate NP stability a compre-
hensive set of complementary characterization techniques are
required which will first be described and compared. Thereafter,
different de facto definitions of NP stability in the literature will
be discussed. After these general aspects, the review describes the
surface modification of superparamagnetic iron oxide NPs with
dispersants of low and high surface affinity and Mw. Special
attention is given to the selection of anchors because of their
importance for the surface modification and stability of sterically
stabilized NPs. In particular, we focus on catechol derived
anchors as they combine high binding affinity to Fe3O4 surfaces
and low desorption rates if properly modified.23 This review
further details how dispersants have been optimized to gain close
control over iron oxide NP stability, size and functionalities by
independently considering the influences of anchors and spacers,
and compares different strategies to functionalize core–shell
NPs. The review ends with insights into the influence of the
stability of superparamagnetic iron oxide NPs, and therefore the
strategy for iron oxide NP stabilization and functionalization, on
their magnetic properties.2. Characterization of nanoparticles
To closely control the assembly of dispersants on the NP surface
and understand its influence on NP size distribution, stability
and functionality, thorough characterization is essential. In
addition, to understand the relation between core size, self-
assembly of dispersants at the NP surface, shell thickness and NP
stability, further parameters such as the dispersant packing
density, core size distribution and core surface roughness have to
be considered.This journal is ª The Royal Society of Chemistry 2011
Fig. 1 Biomedical applications of superparamagnetic iron oxide NPs. Superparamagnetic iron oxide NPs can be used for diagnostic purposes as (a)
magnetic resonance (MR) contrast agent200 (Magnetic resonance in medicine by International Society forMagnetic Resonance inMedicine. Reproduced
with permission of JOHN WILEY & SONS, INC. in the format Journal via Copyright Clearance Center.), (b) for cell separation purposes either as
magnetic NPs (MNPs) or as fluorescently labeled NPs (FNPs) and for therapeutic reasons201 (Analytical chemistry by American Chemical Society.
Reproduced with permission of AMERICAN CHEMICAL SOCIETY in the format Journal via Copyright Clearance Center.), (c) in hyperthermia202
(Journal of controlled release by Controlled Release Society. Reproduced with permission of ELSEVIER BV in the format Journal via Copyright
Clearance Center.) and in drug delivery vehicles where they (d) can be incorporated into the lumen of liposomes203 (reprinted by permission of IOP
Publishing Ltd) or into the bilayer of liposomes.204 (ACS nano by American Chemical Society. Reproduced with permission of AMERICAN
CHEMICAL SOCIETY in the format Journal viaCopyright Clearance Center.) Superparamagnetic iron oxide NPs were shown to trigger release if a (e)
high and (f) low frequency magnetic field is applied.205 (Reproduced by permission of The Royal Society of Chemistry.)
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View Article OnlineThe core size, size distribution and morphology can be char-
acterized with a combination of different techniques such as
transmission electron microscopy (TEM),26 X-ray diffraction
(XRD)26 and scattering techniques such as small angle X-ray
scattering (SAXS)27 and small angle neutron scattering
(SANS).28,29 The hydrodynamic diameter of dispersed NPs (the
effective diameter of the NP when diffusing in water, typically
understood as the sum of the core diameter and twice the shell
thickness) can be assessed with scattering techniques, e.g.,
dynamic and static light scattering (DLS and SLS),30 SANS29Fig. 2 Steric stabilization of iron oxide NPs. (a) Schematic of commercial
Endorem. Superparamagnetic iron oxide NPs are coated with physisorbed disp
leads to reversible adsorption of dextran on the iron oxide NP surface. Further
hydrodynamic diameter is many times larger than the core diameter. (b) Super
core–shell iron oxide NPs. These NPs can be divided into four components n
This journal is ª The Royal Society of Chemistry 2011and X-ray disc centrifugation (XDC).31 The dispersant packing
density can be quantified with thermogravimetry analysis
(TGA)23,32 and SANS.29 To verify that dispersants rather than
impurities or capping agents such as oleic acid are adsorbed on
the NP surface, and thus to assign the mass loss measured with
TGA to the dispersants adsorbed on the NP surface, stabilized
NPs can be analyzed e.g.with Fourier transform infrared (FTIR)
spectroscopy32,33 or, less commonly used, X-ray photoelectron
spectroscopy (XPS).23 To extract information about the disper-
sant packing density and dispersant density profile from SANSly available iron oxide based MR contrast agents such as Feridex and
ersants such as dextran. The poor binding affinity of dextran to iron oxide
more, multiple iron oxide cores are embedded in one cluster. The resulting
paramagnetic iron oxide NPs stabilized with lowMw dispersants result in
amely (1) core, (2) anchors, (3) spacers and optionally (4) functionalities.
Nanoscale, 2011, 3, 2819–2843 | 2821
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View Article Onlineresults, it is highly beneficial to do contrast variation experi-
ments, where the contrast of the core and shell is varied by
changing the ratio of protonated to deuterated solvents and thus
varying the scattering length density of the solvent.34 Alterna-
tively, information about the dispersant packing density on NP
surfaces can be extracted from SANS results acquired with
polarized neutrons.29 Furthermore, the dispersant density profile
can be assessed with SANS measurements.35
Because of the different advantages and disadvantages of each
characterization technique, it is highly beneficial to characterize
NPs with multiple, complementary methods. However, if results
obtained with different methods are directly compared, attention
has to be paid to the precise meaning of the results. Differences
and artifacts can be introduced for example through different
weighting of sizes, model-dependent extraction of parameters
and through sample preparation protocols. Such aspects can lead
to substantial differences in the quantification of a physical
property of the NPs with different techniques.
Scattering techniques reveal intensity weighted averages
(I(q) f r6) and are thus sensitive to large NPs and clusters. X-ray
diffraction (XRD) reveals volume weighted averages (fr3) while
TEM allows direct visualization of number weighted (fr1) struc-
tures. To compare scattering to TEM results for the mean size, the
weighting of the sizes has therefore to be taken into account. This is
only possible, if the core size distribution is known.
TEM reveals direct, model independent information. Prepa-
ration of NP samples for TEM is done through drying on, e.g.,
carbon supported TEM grids, unless TEM samples are prepared
with cryo-preparation techniques. Drying of NP dispersions can
introduce artifacts such as NP agglomeration and inhomoge-
neous assembly of NPs of different sizes. Furthermore, it leads to
a collapse of the dispersant layer that makes it impossible to
accurately determine the wet shell thickness even if the coating
can be visualized with TEM.36
In contrast, scattering techniques allow analyzing NPs directly
in dispersion and are therefore less prone to sample preparation
artifacts and better suited to determine the shell thicknesses.
However, they require model dependent data analysis. SANS
and SAXS data are fitted with form factors. The form factors
assume a certain structure and size distribution of the evaluated
objects. Therefore, accurately done, the data analysis requires
prior knowledge about the shape and structure of the analyzed
objects. By comparing scattering data to a set of models the
dispersant shell density profile can be obtained if the quality of
the scattering data is sufficient. However, the NP concentration
can critically affect the outcome of scattering results. If the NP
concentration is high, multiple scattering significantly influences
light scattering results.37 SANS and SAXS data acquired on
highly concentrated NP dispersions typically comprise a struc-
ture factor contribution that is convoluted with the form factor.38
While the form factor describes the size distribution and shape of
NPs, the structure factor is influenced by inter-particle interac-
tions, clustering and assembly of NPs. Because multiple scat-
tering and structure factor contributions can significantly
influence scattering results, it is very important to prepare
samples such that effects of the NP concentration on the scat-
tering results can be excluded or appropriately accounted for.
The fact that the analysis of data acquired with scattering
techniques is model dependent renders a comparison to data2822 | Nanoscale, 2011, 3, 2819–2843acquired with complementary, model independent techniques
highly advantageous. The comparison of the quantification of
NP parameters obtained with scattering techniques with quan-
tification measured with model-independent techniques for the
same parameter allows checking the validity of the model
assumed to analyze scattering data.
The value of characterizing NPs with different, complemen-
tary techniques can be exemplified on the packing density and
density profile of dispersants adsorbed on NP surfaces. These
parameters can be measured and quantified with SANS.
However, to analyze SANS data, a form factor that comprises
assumptions about the core–shell structure of the NPs including
the dispersant density profile has to be applied to analyze the
scattering data.
The mass ratio of organic to inorganic materials can be
quantified with TGA, although no information on the density
profile can be obtained. To ensure that the mass loss of organic
molecules measured with TGA can exclusively be assigned to
dispersants rather than to impurities or remaining capping
agents, further chemical analysis on the stabilized NPs such as
FTIR or XPS is required.23However, TGA is also sensitive to the
morphology of cores as the dispersant packing density is
normalized to the NP surface area that is calculated from the
mass of NPs assuming a certain core size distribution and shape.
Information of the NP size distribution can only partially be
obtained from TEM images due to unknown potential segrega-
tion effects of NPs during sample preparation. Therefore, the
dispersant packing density and density profile on NPs can only
be revealed with any certainty if NPs are characterized with
multiple methods, such as SANS, TGA, TEM and FTIR
spectroscopy.3. Nanoparticle stability
The term ‘‘stability’’ is used with very different meaning in the
literature on NPs, mostly without explicit acknowledgement of
these differences. NPs are often imprecisely considered stable if
they do not visibly precipitate over a finite period of time.39,40 A
thorough characterization of NP dispersions e.g. with scattering
techniques allows us to define NP stability more precisely.
The importance of the technique and conditions used to
characterize NP stability was exemplified on poly(ethylene
glycol)–hydroxydopamine (PEG–hydroxydopamine) stabilized
superparamagnetic iron oxide NPs. PEG (0.55 kDa)–hydroxy-
dopamine stabilized iron oxide NPs were stable for more than
a year if stored and analyzed at RT.22 However, PEG (5 kDa)–
hydroxydopamine stabilized iron oxide NPs agglomerated if they
were subjected to multiple filtrations (Fig. 3).23 If dispersants
adsorb reversibly at the NP surface, dispersants adsorbed on the
NP surface and dispersants free in solution are in equilibrium. If
NP dispersions are filtered, free dispersants are removed. To re-
establish the equilibrium in the NP dispersion, some of disper-
sants bound to the NP surface desorb leading to a lower
dispersant packing density at the NP surface. The dispersant
packing density at the NP surface decreases with increasing times
NP dispersions are filtered. If the dispersant packing density at
the NP surface drops below a critical value, NPs start to
agglomerate.41 The fact that PEG (5 kDa)–hydroxydopamine
stabilized iron oxide NPs agglomerated if subjected to filtrationsThis journal is ª The Royal Society of Chemistry 2011
Fig. 3 Characterization of the stability of superparamagnetic iron oxide
NPs. The stability of superparamagnetic iron oxide NPs was measured
with DLS at 25 C. (a) The hydrodynamic diameter of PEG (0.55 kDa)–
hydroxydopamine stabilized iron oxide NPs as-stabilized (-:-), after
storage for 1 year in PBS (-◮-) and after storing them for 20 months in
HEPES (-O-).206 (Copyright Wiley-VCH Verlag GmbH & Co. KGaA.
Reproduced with permission.) (b) The stability of superparamagnetic
iron oxide NPs was evaluated as a function of the number of filtrations
performed to remove excessive dispersants of iron oxide NPs stabilized
with PEG (5 kDa)–nitrodopamine (---), PEG (5 kDa)–hydroxydop-
amine (-:-) and PEG (5 kDa)–dopamine (-C-).207 (Nano letters by
American Chemical Society. Reproduced with permission of AMER-
ICAN CHEMICAL SOCIETY in the format Journal via Copyright
Clearance Center.) While PEG–hydroxydopamine stabilized iron oxide
NPs were stable at RT for more than 20 months, they started to
agglomerate after excessive dispersants were removed by more than two
filtrations. This indicates that superparamagnetic iron oxide NPs
agglomerate upon dilution and will lead to adverse consequences if
applied in vivo.
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View Article Onlineindicates that hydroxydopamine adsorbs reversibly on Fe3O4
surfaces. However, if the dispersant packing density at the NP
surface is sufficiently high under the conditions NP dispersions
are stored, then NPs remain long-term stable even if they are
stabilized with reversibly binding anchors such as hydroxydop-
amine (Fig. 3a). These NPs, however, will agglomerate upon
dilution (Fig. 3b).
Applications of superparamagnetic iron oxide NPs in vitro in
cell cultures and in vivo always include high dilutions of NP
dispersions. Therefore, reversible dispersant adsorption that
leads to iron oxide NP agglomeration can have severe adverse
consequences for these applications. Once injected into a living
body, agglomeration of NPs is difficult to assess because NP size
cannot be directly measured anymore. Additionally, once NPs
are exposed to cells or injected into the body NP agglomeration is
convoluted with other effects such as exposure to many different
proteins that potentially adsorb on the NP surface or even
replace dispersants if dispersants are insufficiently anchored to
the NP surface. This then leads to a poorly defined system where
analysis of, e.g., the efficiency of targeting NPs to desired loca-
tions by the addition of ligands to the NP shell is difficult to
separate from effects caused by uncontrolled NP agglomeration
and non-specific protein adsorption on the NP surface. This
illustrates the necessity to characterize NPs stringently, especially
if they are intended for biomedical applications. Additionally, to
be encompassing, the criteria for full colloidal stability of NPs
should include the NP characterization under dilute conditions
and in the presence of sticky macromolecules that are biomedi-
cally relevant.
Iron oxide NP stability is typically evaluated based on DLS
measurements performed at RT at a certain NP concentrationThis journal is ª The Royal Society of Chemistry 2011(Table 1). Especially for in vivo applications, it would be bene-
ficial to measure iron oxide NP stability and size with more
thorough characterization methods. One experimentally easily
accessible possibility to measure NP stability under demanding
conditions is temperature dependent DLS measurements. Such
measurements have been shown to provide a good measure of
binding affinity and reversibility of dispersants on the iron oxide
NP surface, which directly translates into long-term NP stability
at highly diluted concentrations under physiological
conditions.23
In theory, NPs are stable if the inter-particle potential (Utot)
has an energy barrier that is high compared to kBT. In a first
approximation, Utot of NPs contains four contributions, the
attractive van der Waals and magnetic attraction potentials and
the repulsive electrostatic and steric potentials.42,43 If the core
radius, shell thickness, saturation magnetization, z potential and
dispersant density profile are known, these potentials can be
calculated.42–44 Considering the four main contributions to Utot,
NPs can be electrostatically or sterically stabilized to prevent
agglomeration induced through the attractive van der Waals and
magnetic potentials. Optionally, the two stabilization methods
can be combined. Electrostatic NP stabilization is only effective
at low ionic strength concentrations and at pHs far above or
below the IEP of NPs. However, biomedical applications require
NP stability under high salt concentrations and over a range of
pHs. Therefore, NPs intended for these applications have to be
sterically stabilized.45,46 The following section will detail different
approaches and advances in steric stabilization of NPs.4. Steric stabilization of iron oxide nanoparticles
Steric stabilization relies on polymers, so-called dispersants, that
surround NP cores. Dispersants that yield a sufficiently thick
shell around the NP core to overcome the attractive van der
Waals and magnetic potentials impart long-term colloidal
stability under dilute conditions, high salt concentrations and
elevated temperatures. Dispersants used to sterically stabilize
superparamagnetic iron oxide NPs can roughly be divided into
two groups. One group of dispersants consists of repeat units
that have low affinity to the iron oxide NP surface. This leads to
reversible dispersant adsorption. The other group of dispersants
typically consists of a high affinity anchor that is covalently
linked to a low Mw spacer, usually below 10 kDa. Optimized
dispersants result in good NP stability at high ionic strength,
physiological pH and temperature, which are absolute require-
ments for biomedical applications.4.1 Physisorption of high Mw dispersants
Superparamagnetic iron oxide NPs used for clinical applications
are primarily coated with polymers such as dextran,47 alginate,48
chitosan,49 poly(vinyl amine) (PVA)50–52 or poly(acrylic acid)
(PAA),53 or by electrostatically adsorbing charged polymers like
poly(ethylene imine) (PEI) to which subsequently a layer of poly
(ethylene oxide)-b-poly(glutamic acid) (PEO-PGA) can be
adsorbed (Fig. 4).54 These polymers lack a well-defined high
affinity anchor that could irreversibly couple them to the iron
oxide NP surface and typically have a molecular weight
>10 kDa.9 Therefore, such dispersants often encapsulateNanoscale, 2011, 3, 2819–2843 | 2823
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View Article Onlinemultiple cores within one cluster (Fig. 2a). The resulting hydro-
dynamic cluster radius is many times larger than the radius of
individual cores (Fig. 5).19–21 The weak physisorption of the
stabilizing polymer dispersants compromises iron oxide NP
stability,55 leads to protein adsorption onto the core particle and
drastically decreases blood circulation time if applied in vivo.56
The poorly defined NP interface prevents controlled function-
alization in terms of number and presentation of ligands.55
To prevent desorption of dextran from iron oxide NPs,
dextran has been crosslinked after it was adsorbed on the iron
oxide NP surface (Fig. 5a).57 However, the resulting hydrody-
namic diameter was large compared to the core diameter and
control over the dispersant layer thickness difficult. Additionally,
epichlorohydrin, the crosslinking agent used to immobilize
dextran on the iron oxide NPs, is classified as cancerogenic,
mutagenic and reproxotic.58,594.2 Anchored low Mw dispersants
As mentioned in the Introduction a desirable alternative in terms
of resultant size, interfacial stability and ability to present surface
functional groups in a defined manner is lowMw dispersants that
consist of one well-defined anchor covalently linked to a spacer
(Fig. 2b). A representative set of recent work on super-
paramagnetic iron oxide NPs stabilized with such dispersants is
summarized in Table 1.
Low Mw dispersants can be bound to NP surfaces either
through the ‘‘grafting to’’ or the ‘‘grafting from’’ technique
(Fig. 6). For the latter approach, initiators are covalently bound
to the NP surface. Spacers can subsequently be grown in situ, e.g.
by radical polymerization, from initiators that have been
attached to NP surfaces (Fig. 6a).60,61 This approach results in
high dispersant packing densities and therefore good NP
stability, because the brush density is set by the density of
anchors from which the grafting from is initiated. Although it
leads to a desirable high shell density the ‘‘grafting from’’ tech-
nique has some inherent drawbacks. Dispersant characterization
and control over the dispersant polydispersity and layer thick-
ness are difficult. Furthermore, functionalization of stabilized
NPs with different ligands or other functional units and
controlling the density of functional groups presented at the NP
interface are challenging.62
If lowMw dispersants are synthesized prior to their adsorption
on the NP surface, they can be characterized with conventional
chemical characterization methods. Low Mw dispersants can be
grafted to the NP surface without the requirement for in situ
chemistry using suitable anchors (Fig. 6b). This self-assembly
approach has the advantage that it is cost effective, reproducible
and is easy to scale up. Furthermore, the dispersant layer
thickness can be controlled by the spacer configuration, disper-
sant packing density and Mw. A particular advantage of the
‘‘grafting to’’ approach is that the density of one or multiple
surface-presented (bio)ligands can be tailored by co-adsorbing
differently functionalized dispersants in one or several subse-
quent assembly steps.22,63 The polymer grafting density achieved
using the ‘‘grafting to’’ approach has on flat surfaces been shown
to be significantly lower than for the ‘‘grafting from’’ approach.62
This difference in polymer grafting density is a result of the steric
repulsion of adjacent polymer chains that defines the densityNanoscale, 2011, 3, 2819–2843 | 2825
Fig. 4 Weakly adhering high Mw dispersants. Dispersants frequently
used to coat superparamagnetic iron oxide NPs intended for biomedical
applications are: (a) dextran, (b) alginate, (c) chitosan, (d) poly(vinyl
amine), (e) poly(acrylic acid) and (f) polyelectrolytes such as poly
(ethylene imine) (PEI) which electrostatically adsorbs on iron oxide NP
surfaces. Further block-co-polymers such as poly(ethylene oxide)–poly
(glutamic acid) can optionally be electrostatically bound to the PEI shell.
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View Article Onlineachievable for the grafting to approach, but not limiting poly-
mers grown in situ on the surface using grafting from strate-
gies.64,65 The rapidly increasing free volume available to
dispersants on NPs with increasing distance from the core
surface results in a lower steric repulsion of adjacent dispersants.
Therefore, the difference in grafting density between surfacesFig. 5 Superparamagnetic iron oxide NPs stabilized with weakly
adhering high Mw dispersants. (a) Superparamagnetic iron oxide NPs
were individually stabilized with dextran where dextran was crosslinked
after adsorption on the iron oxide NP surface. Crosslinking of dextran
was done to decrease the tendency of dextran to desorb from the iron
oxide NP surface.208 (Reproduced by permission of The Royal Society of
Chemistry.) (b) Superparamagnetic iron oxide NPs were coated with poly
(acrylic acid) (PAA).209 (Copyright Wiley-VCH Verlag GmbH & Co.
KGaA. Reproduced with permission.) In contrast to the cartoons, the
physisorption of high Mw dispersants with low affinity to iron oxide
causes enwrapment of multiple cores, leading to broadly distributed
hydrodynamic diameters many times larger than the core diameter.
2826 | Nanoscale, 2011, 3, 2819–2843modified through the ‘‘grafting from’’ and the ‘‘grafting to’’
approach is expected to decrease with increasing surface curva-
ture (Fig. 7). However, it should persist and limit the maximum
Mw of dispersants that can be used to form a complete shell
around the core with the grafting to method.4.3 Anchors
Irrespective of whether low Mw dispersants are grafted to or
from the surface, they have to firmly adhere to the NP surface
through suitable anchors (Fig. 2b). Ideally, the binding affinity of
anchors is high and the desorption rate koff low so that anchors
can irreversibly bind spacers to uncoated NPs and are able to
replace hydrophobic capping agents such as oleic acid often used
to synthesize monodisperse superparamagnetic iron oxide NPs.26
Naturally, anchors that meet these stringent requirements can be
used both to immobilize initiators on a surface to graft disper-
sants from NP surfaces and to graft polymer brushes to NP
surfaces. Typical anchors to surface modify superparamagnetic
iron oxide NPs described in the literature are catechols66–69 or
catechol derivatives,22,23,70,71 carboxy groups,72–74 phospho-
nates73,75,76 and silanes.77–81 Superparamagnetic iron oxide NPs
individually stabilized with these dispersants are increasingly
used for numerous biomedical applications (Table 1 and Fig. 8).
Despite the central importance to define the stability of the NP
shell and to define the density of functional units on a NP, the
influence of different anchors on iron oxide NP stability was only
recently systematically studied. Catechol derivatives with large
variations in affinity to iron oxide were investigated as anchors
for low Mw PEG based dispersants to stabilize super-
paramagnetic iron oxide NPs.23 Thorough characterization of
iron oxide NP stability and its relation to successful in vivo
application as a function of choice of anchor thus remains scant.
As a consequence of the lack of characterization of anchor
stability, only few irreversibly binding anchors are known.
Therefore, the main part of the literature on MR contrast agents
deals with investigations on shells consisting of reversibly
binding dispersants. One remedy to this which has been tried is
immobilization through multiple reversibly adsorbing anchors.82
Multiple anchors per dispersant decrease the desorption rate of
polymers,82 provided they are interconnected by flexible linkers.
Flexible interconnecting linkers between anchors are required for
simultaneous binding of anchors also to the highly curved
surface of a NP. However, the area multiple anchors occupy is
considerably larger than that of a single anchor. Thus, multiple
anchors might critically decrease the dispersant packing density
on highly curved surfaces where steric repulsion of adjacent
spacers is greatly reduced and therefore dispersant packing
density must be increased to densities approaching that given by
the individual anchors.83
Among the commonly described anchors phosphonic acid has
been reported to be too weak to replace carboxy groups from
iron oxide NP surfaces.84 Furthermore, carboxy groups were
shown to be replaced by proteins85 and performed unfavorably as
anchors to stabilize superparamagnetic iron oxide NPs compared
to catechols and nitrocatechols.23 Silanes pose experimental
difficulties in the assembly of dispersants on the iron oxide NP
surface as they have to be adsorbed in water-free solvents andThis journal is ª The Royal Society of Chemistry 2011
Fig. 6 Modifying iron oxide NP surfaces with lowMw dispersants. LowMw dispersants can be (a) grafted from and (b) grafted to the NP surface. If low
Mw dispersants are grafted from the NP surfaces, initiators are firmly bound to the NP surface. After monomers (m) were added to the NP dispersion
dispersants are grown in situ, typically through a radically initiated chemical reaction. Dispersants grown in situ are densely packed on the NP surface,
however, control over dispersant length, polydispersity and density of functionalities presented at the NP surface is difficult. Alternatively, dispersants
(d) are synthesized prior to the adsorption on the NP surface. These dispersants are grafted to the NP surface. The resulting dispersant packing density is
below that of dispersants grafted from the NP surface. However the grafting to approach allows for close control over the dispersant shell thickness and
density of functionalities presented at the NP surface. The latter is achieved by adsorbing a defined concentration of functionalized dispersants at the NP
surface. The NP surface is subsequently back-filled with non-functionalized dispersants.
Fig. 7 Free volume of dispersants. The free volume of dispersants
adsorbed on (a) NPs and (b) flat surfaces. While the free volume of
dispersants adsorbed on NPs increases conically with increasing distance
to the NP surface, it remains constant for dispersants adsorbed on planar
surfaces.
Pu
bl
ish
ed
 o
n 
31
 M
ay
 2
01
1.
 D
ow
nl
oa
de
d 
by
 E
CO
LE
 P
O
LY
TE
CH
N
IC
 F
ED
 D
E 
LA
U
SA
N
N
E 
on
 1
8/
05
/2
01
5 
10
:2
1:
21
. 
View Article Onlinecan crosslink, which compromises control over the assembly of
silane anchored dispersants.86
In recent years, inspired by the presence of catechols in
organisms for fixation of metals and for surface adhesion,
superparamagnetic iron oxide NPs have increasingly been
surface modified using this chemical motif (Table 1).87 Because of
the biological relevance of DOPA/Fe3+ and dopamine/Fe3+
complexes, their structure88–90 and electronic interactions91,92
have been studied in detail. Furthermore, the crystallographic
and electronic structure of peptides,93 proteins94 and models for
catechol dioxygenases complexed with iron ions89,95–97 have been
reported. Despite their popularity as anchors fueled by biological
inspiration and initial investigations on their application as
dispersant anchors for iron oxide NPs, the suitability of catechols
as anchors to stabilize iron oxide NPs is debated. Iron is well
known to catalyze catechol oxidation leading to semiquinones,
quinones and eventually carboxy-containing products.98–100 In
line therewith, oxidative degeneration of dopamine adsorbed on
iron oxide NPs resulting in a loss of NP stability was reported.101
Recently, cryo-TEM images of PEG-dopamine stabilized Fe3O4
NPs revealed NP agglomeration.102 These reports question the
suitability of dopamine as an anchor for steric stabilization of
superparamagnetic iron oxide NPs. Also surface corrosion of
iron oxide NPs as a result of the replacement of oleic acid by
dopamine has been reported,66 but is unlikely given the weak
affinity of dopamine to surface presented iron ions.23,103
Already in 1976 it was noticed that electronegative substitu-
ents strengthen the iron–catechol bond to an extent where bonds
between nitro-substituted catechols (so-called nitrocatechols)
and iron remained unchanged for 24 h at 25 C which wasThis journal is ª The Royal Society of Chemistry 2011considered to be an irreversible bond.104 It was speculated that
nitrocatechols can act as oxidizing agents which was assumed to
be the reason for this exceptionally strong bond.104 Detailed
studies on the binding of nitrocatechols to iron ions revealed
a significantly lower tendency to generate radicals for nitro-
catechol/iron compared to catechol/iron complexes.105 Based on
complexation studies of these anchors with Fe3+, the increased
complexation strength of electronegatively substituted catechols
compared to unsubstituted counterparts was related to the
increased acidity of the former compounds.106,107 Recently, EPR
studies on superparamagnetic iron oxide NPs coated with
nitroDOPA revealed an enhanced electron density atNanoscale, 2011, 3, 2819–2843 | 2827
Fig. 8 Anchors for lowMw dispersants. Some of the more frequently used and recently described anchors to sterically stabilize superparamagnetic iron
oxide NPs with lowMw dispersants are (a) carboxy groups
210 (Journal of polymer science. Part A, Polymer chemistry by JOHNWILEY& SONS, INC.
Reproduced with permission of JOHN WILEY & SONS, INC. in the format Journal via Copyright Clearance Center.), (b) crosslinked slianes211
(Journal of the American Chemical Society by American Chemical Society. Reproduced with permission of AMERICAN CHEMICAL SOCIETY in
the format Journal via Copyright Clearance Center.), (c) silanes212 (ACS nano by American Chemical Society. Reproduced with permission of
AMERICAN CHEMICAL SOCIETY in the format Journal via Copyright Clearance Center.), (d) hydroxymic acid213 (Copyright Wiley-VCH Verlag
GmbH & Co. KGaA. Reproduced with permission.), (e) phosphonates214 (Journal of the American Chemical Society by American Chemical Society.
Reproduced with permission of AMERICAN CHEMICAL SOCIETY in the format Journal via Copyright Clearance Center.), (f) catechols such as
dopamine215 (Journal of the American Chemical Society by American Chemical Society. Reproduced with permission of AMERICAN CHEMICAL
SOCIETY in the format Journal via Copyright Clearance Center.) and (g) electronegatively substituted catechols like nitrodopamine and nitroDOPA.
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View Article OnlinenitroDOPA anchors and electron depleted iron ions on the NP
surface upon adsorption on iron oxide NPs.108,109 Dopamine is
instead known to be oxidized if adsorbed on iron oxide
surfaces.101
The strong complexation of nitrocatechols to Fe3+ ions and
enhanced electron density at the nitroDOPA anchors have been
shown to directly relate to the high stability of grafted polymer
films when nitrocatechols are used as anchors. The stability of
superparamagnetic iron oxide NPs with shells of PEG-nitro-
DOPA or PEG-nitrodopamine was shown to be much higher
than that of iron oxide NPs stabilized with PEG-DOPA and
PEG-dopamine.23 Follow-up studies revealed that the binding
affinity of anchors to the metal ion of oxides has to be optimized
rather than maximized to achieve good iron oxide NP
stability,108,109 since the anchor with the highest binding affinity
resulted in dissolution of the iron oxide cores. Furthermore, these
studies also indicated that knowledge acquired on anchor/metal
ion complexes108,109 and flat surfaces23 can be translated into the
suitability of anchors to surface-modify respective oxide NPs.
More generally, electronegatively substituted catechols such as2828 | Nanoscale, 2011, 3, 2819–2843nitrocatechols110,111 and chlorocatechols111,112 were reported not
only to bind well to iron oxide surfaces but also to Al2O3 and
TiO2 surfaces, and were used to form polymer brushes on planar
surfaces of the latter.1134.4 Spacers
Apart from anchors, suitable spacers are crucial to achieve good
steric NP stability (Fig. 2b). Spacers have to prevent that NPs get
into too close proximity, where van der Waals and magnetic
attraction interactions start to dominate. If two sterically stabi-
lized cores approach each other, the volumes of the respective
polymer shells are confined. This reduces the entropy of disper-
sants and increases the osmotic pressure between NPs. The
resulting repulsive potential critically depends on the dispersant
density profile, packing density,114 binding reversibility and
solvent quality with respect to the dispersants.115 The design and
optimization of sterically stabilized core–shell NPs would be
greatly facilitated if these parameters were known. Only then can
the inter-particle potentials be calculated.116,117 However, theThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlineliterature on the dispersant density profile of core–shell NPs is
inconclusive.
Polymer density profile on planar surfaces. Numerous theo-
retical118–120 and experimental121 studies on the density profile of
polymers adsorbed on planar surfaces have been published.
Scaling theories applied e.g. by de Gennes resulted in a loga-
rithmically decaying inter-particle potential.116 Self-consistent
field (SCF) theory calculations were used to refine the dispersant
density profile by relaxing the stringent requirement that chain
ends are located at the interface resulting in a parabolic polymer
density profile.119,120,122 Shim and Cates further refined this model
by taking into account the finite extensibility of the polymer
chains and extended it to high polymer coverages.123 Based on
these refined models it was found that with increasing surface
coverage, the density profile changes from a parabolic to a step-
function profile for tightly packed, highly stretched polymers.
Polymer density profile on highly curved surfaces. The scaling
theory applied to NPs resulted in a dispersant density profile
decaying exponentially with increasing distance from the NP
surface.124 Thus, this and follow-up studies showed that the
density profile of dispersants obtained from scaling theories
differs between NPs and flat surfaces.125 However, scaling theo-
ries and the Derjaguin approximation fail if the dispersant chain
dimensions approach or exceed the core diameter, which is
usually the case for NPs sterically stabilized in aqueous media. A
different scaling behavior of chains grafted to NP surfaces was
found by extending the SCF theory126 and through Monte Carlo
simulations.127Detailed information about the dispersant density
profile on NPs can only be extracted if more refined theories than
the de Gennes theory such as the SCF theory are applied.128 Ball
et al. who used the SCF theory129 and Li and Witten who
compared the SCF theory to exact solutions obtained by mini-
mizing the free energy130 found that in the limit of low dispersant
packing densities and high dispersant Mws, the density profile
close to the NP interface is depleted from free polymer chain
ends.
However, the assumption of negligible inter-chain penetration
inherent to the models described above only holds for long chains
and low packing densities. Short chains significantly interpene-
trate adjacent chains, which alters the dispersant density profile.
For polymer chains shorter than 1000 repeat units, deviations
from the parabolic polymer density profile result in an earlier and
gradual onset of repulsive inter-particle forces compared to inter-
particle potentials calculated for parabolic polymer density
profiles.131 Furthermore, the dispersant density profile was pre-
dicted to undergo a smooth change from a parabolic decay at low
surface curvatures and for small or stiff dispersants to a power
law decay similar to that of star polymers if dispersants are
adsorbed on highly curved surfaces or if dispersants are
flexible.115,128
In summary, despite the numerous theoretical studies on the
density profile of polymers adsorbed on highly curved surfaces
and experimental investigations of the density profile of block-
co-polymers132–134 the density profile of polymers adsorbed on
highly curved surfaces is still debated. One of the main reasons
for the inconclusive literature might be the lack of experimental
data on dispersants irreversibly grafted to highly curved surfaces.This journal is ª The Royal Society of Chemistry 2011Reversible dispersant adsorption is likely to change the disper-
sant density profile as the latter is dependent on the dispersant
packing density. Moreover, dispersant density profiles are often
investigated with SANS.135 However, desorbed dispersants also
scatter and therefore contribute to the total scattering curve
measured for core–shell NPs. These desorbed dispersants thus
hamper the analysis of scattering data. If dispersants were irre-
versibly bound to the NP surfaces through suitable anchors, the
dispersant density profile could be assessed e.g. with SANS
experiments.
5. Effect of surface modification of nanoparticles on
their biomedical performance protein resistance
As mentioned above in the section on defining stability, super-
paramagnetic iron oxide NPs for most biomedical applications
have to resist adsorption of biomacromolecules such as proteins
in addition to avoiding aggregation. This property, which often is
referred to as ‘‘stealth’’, is necessary for successful application in
vivo. If plasma proteins such as opsonins are adsorbed on the NP
surface, they induce NP uptake by macrophages, monocytes and
dendritic cells and thus initiate NP clearance.136 Therefore,
protein adsorption significantly decreases the circulation time of
NPs. The requirement of resistance to protein adsorption
precludes electrostatically stabilized NPs because most proteins
express surface charges. This limits effective stabilization strat-
egies to those using sterically stabilizing polymer shells, for which
proteins and other biomolecules have no affinity for the spacer
part of the shell.
The most commonly used dispersant spacer that renders NPs
stealth is PEG.11,21 PEG-modified surfaces exhibit the smallest
attractive van der Waals forces to proteins compared to other
well-known water soluble polymers due to the low refractive
index of PEG.137 Furthermore, it is thought that protein
adsorption leads to confinement of the PEG chains resulting in
an energetically unfavorable entropy decrease.138 Yet another
factor contributing to the ability of PEG to render surfaces
protein resistant is the ordering of water around PEG chains,139
which prevents direct contact of PEG with proteins.140 However,
PEG is known to be prone to degeneration if applied in vivo.141,142
In vitro studies showed that poly(2-methyl-2-oxazoline)
(pMOXA) has similar protein repelling properties to PEG, but is
less prone to degradation.143 Thus, pMOXA is a promising
alternative to PEG for the spacer part of lowMw dispersants for
in vivo applications.
Studies on the influence of shell thickness, dispersant packing
density and dispersant conformation on the protein resistance of
sterically stabilized NPs have to be designed carefully to make
sure that the right conclusions are arrived at. It has to be ensured
that the dispersants are irreversibly and homogeneously adsor-
bed on the NP surface, so that the exchange of dispersants by
proteins can be excluded and the protein resistance unequivo-
cally attributed to the PEG shell.
Protein adsorption has been studied in detail on PEG-modified
planar surfaces where quantitative surface sensitive character-
ization techniques such as XPS and time-of-flight secondary ion
mass spectroscopy (ToF-SIMS) are at hand.82,144,145 It was found
that protein adsorption decreases almost linearly with increasing
ethylene glycol (EG) monomer surface density. If planar surfacesNanoscale, 2011, 3, 2819–2843 | 2829
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View Article Onlineare coated with EG surface densities >15–30 nm2, they become
protein resistant.82,144
The existence of a threshold value for the EG density for
protein resistance on surfaces has direct consequences on the
PEG packing density. In fact, a high PEG packing density has
been shown to be crucial to prevent adsorption especially of
small proteins. The adsorption of large proteins on surfaces was
shown less sensitive to the PEG packing density.145–148 Further-
more, a threshold value for the EG density also closely relates to
the Mw required to render surfaces protein resistant. The higher
the PEG Mw, the lower the polymer packing density can be to
impart complete protein resistance to PEGylated surfaces.
Generally, protein resistance requires that PEG is in the brush
regime where the distance between adjacent chains D is smaller
than the Flory radius RF of the polymers.
118,149
Similarly, the PEGMw and the EG surface density were shown
to be crucial parameters for the protein resistance and thus
circulation time of NPs. The EG density on NPs might have to be
higher than on planar surfaces to render NP surfaces protein
resistant due to the high surface curvature of NPs that leads to
a conically increasing free volume for dispersants starting from
the NP surface (Fig. 7). However, the general principles for
protein resistance described above are expected to hold irre-
spective of the surface curvature.
This was exemplified in a study, where protein resistance of
100 nm diameter poly(lactic acid) (PLA) NPs stabilized with
PEG (2 kDa) could only be obtained if the PEG packing density
was $0.2 molecules nm2.150 For lower PEG packing densities,
the circulation time increased with increasing PEG Mws due to
an increased EG density.56 Protein adsorption on 200 nm
diameter PLANPs could be significantly decreased if at least 5 wt
% PEG (5 kDa) was added to the PLA NP surface.55 At this
concentration, PEG should be in the brush regime as the distance
between two PEG chains was D ¼ 1.4 nm56 whereas RF of PEG
(5 kDa) ¼ 5.1 nm and the curvature of the core is rather low.
However, due to steric repulsion, the PEG packing density will
also decrease on NP surfaces with increasing PEG Mw. Too low
PEG packing density in itself compromises NP stability and sets
an upper limit to the suitable Mw range.
41 This is a particular
problem if the dispersant Mw is so high that only few polymer
chains can attach during grafting or remain attached after
hydration. Therefore, PEG Mws between 1.9 and 5 kDa were
found to be optimal to surface modify superparamagnetic iron
oxide NPs intended for biomedical applications.71,146,151 NPs
stabilized with PEGylated dispersants that fulfill these require-
ments of high dispersant packing densities and PEG Mws
between 1.9 kDa and 5 kDa showed prolonged circulation
times.152,1535.1 Biodistribution—relation to nanoparticle size and stability
In addition to the surface chemistry that determines the affinity
of proteins to adsorb on NP surfaces, NP size, shape,50,154 and
surface charge155 also determine the fate of NPs in vivo.156 While
particles larger than 200 nm are rapidly cleared by the spleen,
NPs smaller than 10–50 nm are generally removed from the body
through extravasion and renal clearance.11,58 The optimal
hydrodynamic diameter range for in vivo applications of intra-
venously injected NPs that require prolonged blood half-life2830 | Nanoscale, 2011, 3, 2819–2843times is therefore 10–100 nm. The hydrodynamic diameter range
together with the range of dispersant shell thicknesses that lead
to good NP stabilities described above limit the respective core
and spacer sizes of NPs.
PEG stabilized superparamagnetic iron oxide NPs with
a hydrodynamic diameter between 30 and 50 nm have been
reported to mainly end up in the liver and spleen if administered
in nude mice.157 Their concentration in the liver and spleen
decreased to 40% and 20%, respectively, of the injected dose
within 72 h.157 However, the clearance of PEGylated NPs was
shown to depend on the affinity of dispersant anchors to the NP
surface.136,158 If PEG was covalently attached to the surface, the
NP circulation time was substantially prolonged compared to
that of NPs where PEG was physisorbed to the surface.56,158 The
fast clearance of the latter NPs was assigned to the fact that
proteins could replace physisorbed PEG.
Similar to PEG stabilized superparamagnetic iron oxide NPs,
dextran coated, agglomerated iron oxide NPs accumulated in the
liver and spleen. In addition to slow clearance and a tendency to
agglomerate,159 dextran coated NPs have also been shown to
induce differentiation of monocytes into macrophages.556. Effect of nanoparticle stability on magnetic
properties
One essential parameter that describes the magnetic response of
superparamagnetic iron oxide NPs is their saturation magneti-
zation (Ms). The higher the Ms of superparamagnetic iron oxide
NPs, the easier they can be magnetically separated and ferried to
desired locations. Furthermore, a highMs of superparamagnetic
iron oxide NPs locally induces higher magnetic field gradients if
dispersed in solutions and subjected to an external homogeneous
magnetic field. These magnetic field perturbations are respon-
sible for changed relaxivities r2 of water molecules measured in
MRI. Thus, the higher the Ms of superparamagnetic iron oxide
NPs with everything else being equal, the more effective they are
as MR contrast agents.11
The magnetic properties of NPs depend on the composition,
size and shape of the NP core.11 However, Ms of super-
paramagnetic iron oxide NPs is always below that of the
respective bulk materials and decreases with decreasing core
size.160 This decrease was assigned to surface anisotropy
effects161,162 that become increasingly important with increasing
surface to volume ratio and thus with decreasing NP size.6.1 Effect of surface modification on saturation magnetization
of superparamagnetic iron oxide nanoparticles
The Ms has been shown to decrease if superparamagnetic iron
oxide NPs are sterically stabilized.22,163 However, to directly
compare Ms values of stabilized and unstabilized super-
paramagnetic iron oxide NPs, theMs has to be normalized to the
mass of iron oxide to account for the lower wt% of NP cores in
sterically stabilized compared to bare iron oxide NPs. The lower
Ms of sterically stabilized superparamagnetic iron oxide NPs
likely is related to interactions of anchors with surface bound
iron ions that influence the magnetic properties of the iron oxide
NP surface layer.108,109Therefore, iron oxide NP stability and size
have to be traded off against high Ms values.This journal is ª The Royal Society of Chemistry 2011
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View Article OnlineOne common way in the literature to demonstrate good
magnetic properties of stabilized superparamagnetic iron oxide
NPs is to show their attraction in solution to a small tabletop
magnet. However, individually stabilized superparamagnetic
iron oxide NPs have too low Ms to be strongly attracted by
a small tabletop magnet. In contrast, agglomerates are readily
attracted by such magnets.22,39 Therefore, tests in which iron
oxide NPs are rapidly cleared from solutions using tabletop
magnets not only indicate good magnetization of the super-
paramagnetic iron oxide NPs but also poor NP stability.6.2 Relaxivity
Superparamagnetic iron oxide NPs enhance contrast in MR
images by changing the relaxation times r1 and r2 of adjacent
water molecules.11 r1 is mainly determined by the exchange rate
of water molecules in the first hydration shell of super-
paramagnetic iron oxide NPs. Thus, it depends on the accessi-
bility of water molecules to the iron oxide core surface.
Commercially available superparamagnetic iron oxide NPs are
coated with the reversibly adsorbing dextran that allows water to
readily exchange also in close proximity to the NP surface
(Fig. 2a and 5). However, if superparamagnetic iron oxide NPs
are stabilized with low Mw dispersants through irreversibly
binding anchors and at high dispersant packing densities, the
accessibility of water molecules to the iron oxide surface is
reduced. Therefore, r1 contrast of iron oxide cores individually
stabilized with lowMw dispersants that are irreversibly adsorbed
at the iron oxide NP surface at high packing densities is lower41
compared to dextran coated iron oxide NPs.
Table 2 provides an overview of relaxivities of some
commercially available superparamagnetic iron oxide NPs
compared to individually stabilized iron oxide NPs.13,16 It is well
known that r2 increases with increasing iron oxide NP size.
164,165
Furthermore, iron oxide NP agglomeration166,167 and controlled
crosslinking of iron oxide NPs168 have also been shown to
increase r2. This was confirmed by Monte Carlo simula-
tions.169,170 Therefore, r2 of individually stabilized super-
paramagnetic iron oxide NPs is lower compared to that of
commercially available, dextran coated, agglomerated NPs
(Table 2). However, lowMw dispersants that are firmly bound to
the iron oxide NP surface through suitable anchors allow inde-
pendent tuning of the core diameter and shell thickness. This
opens up the possibility to increase r2 without sacrificing iron
oxide NP stability, by increasing core size up to the limit whereTable 2 Comparison of relaxivities of commercially available superparamag
individually stabilized superparamagnetic iron oxide NPs with defined core s
Trade name dcore/nm dhydrodynamic/nm Dispersan
Feridex/Endorem 4.8–5.6 80–150 Dextran
Resovist 4.2 62 Carboxyd
Sinerem 4–6 20–40 Dextran
Individually
stabilized iron oxide NPs
11 Dextran
Individually
stabilized iron oxide NPs
5 26 PEG(5)-n
Individually
stabilized iron oxide NPs
10 28 PEG(5)-n
This journal is ª The Royal Society of Chemistry 2011iron oxide NPs become ferromagnetic. Therefore, individually
stabilized superparamagnetic iron oxide NPs41 can have r2 values
comparable to those of commercially available iron oxide based
MR contrast agents,13,16 since the former have a hydrodynamic
diameter many times smaller than the commercially available
analogues (Table 2).
The influence of the dispersant shell on the relaxivity is still
debated.171,172 r2 values reported by Duan et al. were claimed to
depend on the hydrophilicity of the polymer shell.172 However,
relaxivity did not change systematically with the hydrodynamic
diameter of superparamagnetic iron oxide NPs.172 In contrast,
LaConte et al. reported a decrease in r2 with increasing hydro-
dynamic diameter for PEG withMw < 1 kDa.
171 Iron oxide NPs
stabilized with PEGs withMws between 1 and 5 kDa had within
experimental error the same relaxivities. However, it is ques-
tionable, whether PEG spacers withMw < 1 kDa result in stable
NPs. Thus, the dependence of r2 on the dispersant shell thickness
likely is related to the limited stability of NPs coated with PEGs
that have Mw < 1kDa rather than to the fact that the PEG shell
slows down the water exchange rate.6.3 Specific adsorption rate (SAR)
The specific adsorption rate (SAR) determines how effectively
NPs generate heat if they are exposed to an alternating magnetic
field (AMF). The SAR is the most important property for the use
of superparamagnetic iron oxide NPs in hyperthermia treatment
or for triggering release of cargo encapsulated in thermores-
ponsive drug delivery vehicles.58
For superparamagnetic NPs that have small magnetic
anisotropies, the SAR at a fixed frequency n is proportional to
the relaxation time s of NPs.58 s increases with increasing core
size of the NPs.173 Therefore, the SAR increases with increasing
NP size up to a critical core diameter dcrit. If s > (2pn)1, the Neel
and/or Brownian relaxations of NPs cannot follow the alter-
nating magnetic field and thus the SAR then rapidly decays with
increasing s and therefore NP size.58,173
Iron oxide NP agglomeration is known to increase interpar-
ticle interactions174 which decreases Neel relaxation losses at
frequencies typically used for SAR applications.175 Thus, steric
stabilization of individual iron oxide cores increases the SAR as
was experimentally shown on agglomerated and with poly
(methyl methacrylate) (p(MMA)) stabilized superparamagnetic
iron oxide NPs.175netic iron oxide NPs stabilized with physisorbed dispersants to selected
izes
t r1/mMFe s
1 r2/mMFe s
1 r2/r1 Ref.
24 98 4.1 255
extran 24–25 107–151 4.5–6 255, 256
23 53 2.3 255, 256
22 44 2.0 257
itroDOPA 12 82 6.8 258
itroDOPA 18 204 11.3 258
Nanoscale, 2011, 3, 2819–2843 | 2831
Pu
bl
ish
ed
 o
n 
31
 M
ay
 2
01
1.
 D
ow
nl
oa
de
d 
by
 E
CO
LE
 P
O
LY
TE
CH
N
IC
 F
ED
 D
E 
LA
U
SA
N
N
E 
on
 1
8/
05
/2
01
5 
10
:2
1:
21
. 
View Article Online7. Iron oxide nanoparticle functionalization
7.1 Surface presentation of targeting ligands
Different types of unfunctionalized superparamagnetic iron
oxide NPs stabilized with weakly adsorbed highMw dispersants,
such as dextran, are FDA approved.176,177 They are used in clinics
as negative MR contrast agents to detect lesions mainly in the
liver and spleen.58,176 A comprehensive list of non-targeted
commercially available and in research labs developed targeted
iron oxide based MR contrast agents, was recently published by
Laurent et al.58
Dispersants adsorbed on NP surfaces allow for functionali-
zation of NPs, an option that becomes increasingly important for
many applications especially in the biomedical field.6,58,178
Potential targeting moieties are antibodies,179 peptides,80,180–182
aptamers,183 DNA168,184 and RNA185 sequences. They are
thought to be able to specifically bind appropriately functional-
ized NPs to desired locations.
Reports where in vivo targeting of superparamagnetic iron
oxide NPs is claimed are numerous. However, the vast majority
of iron oxide NPs are targeted towards the liver, kidney or lymph
nodes, locations they naturally end up during clearance.186
Alternatively, iron oxide NPs were targeted to tumors and cancer
cells, where they naturally accumulate due to the enhanced
permeation retention (EPR) effect (Table 3).58,187 Proving specific
targeting to such organs is therefore difficult as increased accu-
mulation can occur also without specific binding to a target.
Table 3 provides an overview of superparamagnetic iron oxide
NPs individually stabilized with lowMw dispersants and selected
examples of iron oxide NPs coated with dextran that were
subsequently functionalized with ligands covalently bound to the
dextran shell.
Key to successful targeting of NPs just as for successful
stabilization is that functionalities are irreversibly bound to the
NP surface. Only then can desorption of functional units from
NP surfaces be prevented. Desorbed targeting ligands can block
receptors before functionalized NPs reach these locations and the
loss of ligands results in lower affinity of these NPs to the tar-
geting sites. Irreversible binding of functionalities to NP cores
can be fulfilled if spacers and functionalities are bound to NP
surfaces through suitable anchors. If NPs are stabilized with low
Mw dispersants, the ligand density presented at the NP surface
can be closely controlled by co-adsorbing functionalized and
unfunctionalized dispersants to the NP surface at defined molar
ratios.22 This is in stark contrast to NP surfaces coated with
physisorbed high Mw dispersants where the serpentine,
constantly changing conformation prevents efficient addition
and controlled presentation of ligands at the NP interface.188
One of the experimentally easiest and most versatile ways to
functionalize NPs is the avidin–biotin coupling strategy. The
avidin–biotin bond is one of the strongest non-covalent bonds,
with a dissociation constant of Kdz 10
15 M.189,190 For practical
purposes, this is an irreversible bond, at least in the absence of
external forces. Because many ligands are commercially available
in a biotinylated form, this functionalization method is often
used for research purposes.22,191,192
Individually stabilized NPs functionalized through the biotin–
avidin coupling strategy possess a layer-by-layer build-up. The2832 | Nanoscale, 2011, 3, 2819–2843different layers are modularly interchangeable and allow to
firmly attach active ligands to NP cores. One of the main
disadvantages of NP functionalization through the biotin–avidin
coupling strategy is the risk that NPs agglomerate during the
layer-by-layer assembly and subsequent purification of func-
tionalized NPs. Several different avidin derivatives are
commercially available of which the least non-specifically inter-
acting is neutravidin, but they all possess multiple binding sites
for biotin.190 During and after biotinylated NPs are coated with
neutravidin, more than one biotinylated NP can therefore bind
to the same neutravidin leading to agglomeration (Fig. 9a). To
prevent crosslinking during coating of biotinylated NPs with
neutravidin, biotinylated NPs have to be slowly added to
a solution containing an excessive amount of neutravidin, fol-
lowed by thorough washing to remove excessive neutravidin. The
resulting NPs have to be surrounded by a complete neutravidin
monolayer.22
Neutravidin coated NPs furthermore bear the risk to crosslink
while they are incubated with biotinylated ligands with multiple
biotin sites per molecule (Fig. 9b). Large ligands such as anti-
bodies always present multiple biotin sites per molecule unless
they are specifically engineered. Since such ligands are also
expensive they cannot be dispersed at high concentrations to
reduce the risk of crosslinking by following the strategy devel-
oped for the neutravidin functionalization step (Fig. 9b). Thus,
the likelihood that biotinylated NPs crosslink during or after
functionalization with biotinylated ligands though an avidin
intermediate layer is high. Similar things were reported for bio-
tinylated liposomes that were functionalized with biotinylated
antibodies.193,194
Furthermore, for in vivo applications, functionalized NP
dispersions typically have to be up-concentrated many times.
This adds an additional preparation step and increases the risk
for NP crosslinking. Needless to say that if dispersants are
reversibly bound to the NP surface, dissociation of biotinylated
dispersants that are linked to neutravidins also results in free
neutravidin in solution which can be another cause for agglom-
eration and reduced targeting efficiency. Thus, while NP func-
tionalization through the avidin–biotin coupling strategy is
experimentally easy and versatile, it is only suited for applica-
tions that do not require long term NP stability and where NPs
are applied under dilute conditions. As a neutravidin coating is
likely to reduce the stealth property of NPs, neutravidin coated
NPs are mainly suitable for in vitro applications where NPs do
not have to be stealth.
The loss of stealth properties is minimized if the number of
proteins in the ligand shell is minimized. This can be achieved by
covalently linking ligands directly to the stealth PEG dispersant
shell at a controlled density instead of using an avidin interme-
diate layer (Fig. 10). In the former case, specific and non-specific
protein adsorptions to NPs are assumed to be limited to the
added ligands. Superparamagnetic iron oxide NPs functionalized
with covalently bound ligands have so far typically been coated
with dispersants such as dextran that lack well defined anchors
(Table 3).179 They therefore make a controlled surface presen-
tation of functionalities difficult.182
In contrast, superparamagnetic iron oxide NPs that are
stabilized with low Mw dispersants, such as PEG-silanes, allow
controlled presentation of ligands at the NP interface. This wasThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlinedemonstrated e.g. on chlorotoxin functionalized iron oxide
NPs.9,78 Their performance and uptake was subsequently studied
in vitro in cell assays.9,80 A controlled surface presentation of
ligands is thought to increase the targeting efficiency by
decreasing the risk that ligands are buried in the dispersant shell.
Furthermore, it allows for a closer control over changes in the
hydrodynamic diameter of NPs upon functionalization (Fig. 11)
and enables optimizing the number of ligands bound to one NP
to ensure sufficient binding affinity while minimizing non-specific
interactions.
Because the hydrodynamic size of superparamagnetic iron
oxide NPs significantly influences NP uptake by cells,195 control
over the hydrodynamic diameter of NPs upon functionalization
is crucial. Ligands, such as antibodies and peptides, are often
comparable in size to the iron oxide NPs185 and their coupling
can significantly change the hydrodynamic size (Fig. 11). Anal-
ogous to the case described for biotin–avidin functionalization
above, ligands can also crosslink and cluster individually stabi-
lized NPs if they bear multiple chemically reactive groups per NP
(Fig. 11c). This significantly increases the hydrodynamic diam-
eter. It prevents elucidation of the effect of ligands on the bio-
distribution and clearance of functionalized NPs as this is always
convoluted with the increase in NP size. Therefore, it is of highest
importance to measure the hydrodynamic diameter and z
potential of NPs before and after ligands are coupled to their
shells. Only if the NP size and surface charge are not significantly
altered by the attached ligands can differences in the NP bio-
distribution and clearance rate unequivocally be attributed to
a targeting effect. However, the hydrodynamic size of super-
paramagnetic iron oxide NPs after ligands were coupled to their
shells is often not reported (Table 3). A few in vitro and in vivo
studies where this has been done are described below.
The hydrodynamic size and z potential of iron oxide NPs
functionalized with chlorotoxin185 and changes in the hydrody-
namic size and surface charge upon assembling cRGD func-
tionalized iron oxide NPs196 were reported. Preferred binding of
cRGD functionalized over non-functionalized iron oxide NPs
towards cancer cells was shown in in vitro studies. Because of
similar values of the z potential and hydrodynamic size of
unfunctionalized and cRGD functionalized iron oxide NPs, the
preferred binding of the latter NPs towards cancer cells can be
assigned to specific binding of these NPs.
An alternative way to elucidate binding specificity of NPs is to
functionalize them with different peptide sequences of similar
size and charges. A comparison of the binding of NPs func-
tionalized e.g. with native and scrambled RGD sequences to cells
allows us to assess the binding specificity of such NPs.180
Superparamagnetic iron oxide NPs have most frequently been
functionalized with peptides (Table 3). The increasing number of
reports on peptide functionalized iron oxide NPs might be
related to the feasibility to assemble NPs that have a high affinity
towards receptors in a controlled way, thanks to the smaller size
and that peptides can be designed and chosen to have only a few
coupling sites per molecule. For steric reasons, the large size of
antibodies only allows a limited number to be attached to the NP
surface. However, the binding affinity of functionalized NPs was
greatly enhanced if NPs could bind to receptors through the
attachment of multiple ligands compared to NPs functionalized
with a low ligand density where statistically only one ligand perThis journal is ª The Royal Society of Chemistry 2011
Fig. 9 Schematic of superparamagnetic iron oxide NPs that crosslinked during functionalization. (a) Biotinylated superparamagnetic iron oxide NPs
can crosslink during functionalization with avidin derivatives if the molar ratio of avidins : biotinylated iron oxide NPs is too low. (b) Individually
stabilized biotinylated superparamagnetic iron oxide NPs that are surrounded by an avidin layer can crosslink during functionalization with biotinylated
ligands if the ligands bear more than one biotin per molecule. (c) Superparamagnetic iron oxide NPs can also crosslink when ligands are covalently
bound to the NP shell if the ligand contains more than one chemically active group per molecule. Thus, only if ligands contain exactly one chemically
active group per molecule through which these ligands can be bound to the NP shell, can crosslinking and thus uncontrolled agglomeration of func-
tionalized superparamagnetic iron oxide NPs be completely avoided.
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View Article OnlineNP was able to bind to the receptor.181 Therefore, the limited
number of antibodies that can be immobilized on the NP surface
in an orientation that allows ligands to bind to the respective
receptor hamper efficient NP targeting. Furthermore, proteins
can non-specifically adsorb to antibodies which reduces the
circulation time of antibody functionalized NPs. Therefore,
ligands that have lower Mw compared to antibodies might be
more promising to use as targeting ligands for super-
paramagnetic iron oxide NPs.1817.2 Multifunctional iron oxide nanoparticles
It is often desirable, especially for research purposes, to add
multiple labels (imaging modalities), such as fluorophores or
radiotracers to iron oxide NP surfaces. A second modality helps
us to unequivocally locate such contrast agents and differentiate
them from imaging artifacts. The addition of second labels
renders superparamagnetic iron oxide NPs multifunctional only
if the additional labels are irreversibly bound to their surfaces
(Fig. 12).12 Table 4 provides an overview of selected multifunc-
tional superparamagnetic iron oxide NPs that were tested in vitro
in cell cultures or in vivo.
Combining multiple labels on superparamagnetic iron oxide
NPs can lead to undesirable crosstalk. Recently, the combi-
nation of plasmonic and magnetic properties within a NP hasThis journal is ª The Royal Society of Chemistry 2011been demonstrated by spacially separating a plasmonic shell
from the iron oxide core through a dielectric polymer layer.197
If superparamagnetic iron oxide NPs are functionalized e.g.
with near infrared (NIR) fluorescent molecules, fluorescence is
hampered by the absorption of light caused by the iron oxide
cores. Iron oxide has been reported to quench CY5.5 and
FITC if less than two fluorophores were attached to one iron
oxide core.198 Based on the increased fluorescence observed if
these fluorophores were cleaved from the iron oxide NP
surface, this quenching was assigned to non-radiative iron
oxide–fluorophore interactions. However, for such studies, it is
crucial to control the distance of the fluorophores to the iron
oxide cores. This could be achieved with low Mw dispersants
where fluorophores can be covalently linked to the spacer at
a defined distance and minimize the risk that fluorophores
directly bind to iron oxide surfaces e.g. through OH or SO3
groups.
Purification of superparamagnetic iron oxide NPs stabilized
with high Mw dispersants is crucial but difficult. Rigorous
purification of such iron oxide NPs risks agglomeration,
because the physisorbed dispersants adsorb reversibly at the
NP surface. This might be one of the reasons why super-
paramagnetic iron oxide NPs coated with non-crosslinked
dextran or other high Mw dispersants often were not purified
with columns (Table 4). However, rigorous purification isNanoscale, 2011, 3, 2819–2843 | 2835
Fig. 10 Functionalization of superparamagnetic iron oxide NPs. Additional functionalities can be imparted on superparamagnetic iron oxide NPs by
covalently linking e.g. (a) fluorophores,216 (b) radiotracers217 (reprinted with permission of Mary Ann Liebert, Inc) and (c) ligands such as antibodies218
(Journal of the American Chemical Society by American Chemical Society. Reproduced with permission of AMERICAN CHEMICAL SOCIETY in
the format Journal via Copyright Clearance Center.) to the dispersant shell. These additional functionalities can be linked to the dispersant shells with
a variety of different chemical reactions. Often used methods are (a) click chemistry or (b and c) thiol, maleimide coupling reactions. Superparamagnetic
iron oxide NPs were coated with (a and b) dextran and (c) dimercaptosuccinic acid (DMSA) prior to functionalization.
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View Article Onlinerequired to eliminate free fluorophores or non-complexed
radiotracers. This was exemplified in a study by Jarrett et al.
where non-complexed 64Cu could not be removed by centrifu-
gation but required purification of iron oxide NPs by column
separation.199 Therefore, it is highly beneficial to bind second
labels to iron oxide cores through dispersants that adsorb on2836 | Nanoscale, 2011, 3, 2819–2843the NP surface in a well-defined way through suitable, high
affinity anchors. If closely packed, these dispersants then allow
estimating the distance between optically active tracers and
magnetic cores. This is thus key also for controlled assembly of
multimodal imaging agents, and ensures that two or more
modalities can be co-localized.This journal is ª The Royal Society of Chemistry 2011
Fig. 11 Effect of functionalization on the size of superparamagnetic iron oxide NPs. (a) The dispersant shell consisting e.g. of amine terminated PEG-
silanes219 (Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission.) can be of comparable size to the iron oxide core.
Therefore, the hydrodynamic diameter of sterically stabilized NPs is considerably larger than the core size. (b) Targeting ligands such as chlorotoxin,
siRNA and fluorophores can have a similar size to that of the iron oxide cores. Therefore, the hydrodynamic diameter of functionalized NPs can be
significantly larger than that of unfunctionalized NPs.220 (Biomaterials by Biological Engineering Society. Reproduced with permission of PERGA-
MON in the format Journal viaCopyright Clearance Center.) (c) The increase in hydrodynamic diameter of iron oxide NPs upon coupling ligands to the
dispersant shell is experimentally shown on superparamagnetic iron oxide NPs stabilized with PEG (5 kDa)–nitroDOPA that were further function-
alized with neutravidin (green) followed by biotinylated antibodies (blue).
Fig. 12 Assembly of multifunctional contrast agents. Superparamagnetic iron oxide NPs were surface modified with (a) triblock co-polymer consisting
of poly(butyl acrylate), poly(ethylene acrylate) and poly(methacrylic acid) yielding TRIPO221 (Biomaterials by Biological Engineering Society.
Reproduced with permission of PERGAMON in the format Journal via Copyright Clearance Center.), (b) dopamine followed by the adsorption of
human serum albumin (HSA)222 (Biomaterials by Biological Engineering Society. Reproduced with permission of PERGAMON in the format Journal
via Copyright Clearance Center.) and (c) polyaspartic acid (PASP) (reprinted by permission of the Society of Nuclear Medicine from ref. 223).
Additional functionalities such as fluorophores, radiotracers and ligands were covalently coupled to the dispersant shell through NH2–N-hydroxy
succinimide (NHS) and maleimide–SH coupling reactions.
This journal is ª The Royal Society of Chemistry 2011 Nanoscale, 2011, 3, 2819–2843 | 2837
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View Article Online8. Conclusion
The increasingly demanding and versatile requirements imposed
on superparamagnetic iron oxide NPs intended for biomedical
applications require close control over the NP size, structure and
surface properties. The key requirement is colloidal stability
under physiological conditions which can only be met if iron
oxide NPs are sterically stabilized with dispersants that firmly
and for practical purposes irreversibly bind to the NP surface.
Dispersants consisting of a suitable anchor covalently linked to
a spacer have been shown to meet this stringent requirement.
A close control over the assembly of dispersants at the NP
surface allows individual tuning of the core size and shell thick-
ness. While the magnetic response of superparamagnetic iron
oxide NPs is directly related to the core size, the shell thickness
critically affects NP stability and biodistribution. Thus, within
the limit of superparamagnetic cores, magnetic response of
individually stabilized iron oxide NPs can be maximized by
increasing the core size without compromising NP stability. This,
however, is only possible if iron oxide NPs are stabilized with
optimized dispersants that consist of an irreversibly binding
anchor covalently linked to a spacer long enough to provide
good steric stability but still small enough to allow high disper-
sant packing density. If these requirements are fulfilled, indi-
vidually stabilized superparamagnetic iron oxide NPs can be
used as highly stable, well-dispersed NPs for a multitude of
biomedical applications. End-grafted and irreversibly bound
dispersants further allow for controlled functionalization of
individually stabilized NPs. This is achieved by simply adjusting
the molar ratio of differently functionalized and unfunctional-
ized dispersants that are grafted to the iron oxide NP surface.
Thorough characterization of the NP size and surface charge is
indispensable for studies where effects of dispersants and ligands
are to be studied. Only if NP size and surface charge are similar
before and after functionalization can differences in the bio-
distribution and circulation time be solely assigned to the pres-
ence of ligands presented at the NP surfaces. High iron oxide NP
concentrations are required for biomedical applications. There-
fore, individually stabilized superparamagnetic iron oxide NPs
should be functionalized with an optimized low density of
ligands and second labels that only possess one chemically active
group per molecule. Only then can agglomeration through
crosslinking be avoided, and good iron oxide NP stability and
close control over the NP size be ensured.
The colloidal and interfacial stability of superparamagnetic
iron oxide NPs also has to be considered when evaluating
magnetic properties such as saturation magnetization. The
saturation magnetization is increased by agglomeration of iron
oxide NPs, affecting relaxivity, magnetic separation and SAR, all
of relevance for biomedical applications. Furthermore, the
anchor chemistry can affect the magnetization through strong
interactions with the ions in the surface layer of the magnetic
core.
In summary, recent advances in the layer-by-layer assembly of
superparamagnetic iron oxide NPs now allow rational design
and independent optimization of the many different required
properties of iron oxide NPs. The key aspect is a well-defined
dispersant shell which consists of spacers that are sufficiently
strongly anchored to the iron oxide NP at high packing densities.This journal is ª The Royal Society of Chemistry 2011
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View Article OnlineIf this requirement is fulfilled, additional imaging modalities can
be added to the NP surface in a controlled way by co-adsorbing
differently end-functionalized dispersants. This modular
approach greatly enhances the versatility of applying NP plat-
forms to the various biomedical applications they are being
designed for, but requires thorough interdisciplinary character-
ization that is not always performed for every material study.
The critical evaluation in this review of the current state-of-the-
art in the field, however, demonstrates that there is great
potential in the near future for further breakthrough develop-
ments in NP design for biomedical and other applications.References
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